Peter Riedell, MD, discusses the effect of time to relapse in patients with mantle cell lymphoma after frontline high-dose rituximab-based therapy and autologous hematopoietic cell transplantation.
Peter Riedell, MD, an assistant professor of medicine at the University of Chicago Medicine, discusses the effect of time to relapse in patients with mantle cell lymphoma (MCL) after frontline high-dose rituximab (Rituxan)-based therapy and autologous hematopoietic cell transplantation (AHCT).
The Center for International Blood and Marrow Transplant Research database allowed Riedell and his fellow investigators to look at unique data points. Their analysis showed the impact of relapse on overall survival (OS) at 6-month intervals. Riedell says what was interesting to him and his colleagues was that the multivariate analysis showed that the impact on OS varied with time and was the greatest at the early time points after patients with MCL received AHCT. The investigators observed that those who relapsed by the 6-month, 12-month, or 18-month landmark time points after AHCT had the worst outcomes overall.
Patients with MCL who were considered older, 60 years old and above, had worse OS at the various landmark time points. This was consistent with other previously published data, according to Riedell. The median age in the analysis was 60 years (range, 29-78).
Cretostimogene Grenadenorepvec Shows High CR Rate in BCG-Unresponsive NMIBC
July 17th 2024Mark D. Tyson, II, MD, MPH, discussed treatment with cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ and data from the BOND-003 trial.
Read More
Phase 3 VERIFY Trial Investigates Rusfertide’s Potential in Polycythemia Vera
July 16th 2024In an interview, Aniket Bankar, MD, discussed the background, design, and goals of the phase 3 VERIFY trial of the hepcidin mimetic rusfertide for the treatment of patients with polycythemia vera.
Read More
Examining Breast Cancer Recurrence Detection Methods in a Community Oncology Setting
July 12th 2024In an interview with Targeted Oncology, Ali Duffens, MD, discussed findings from a study which investigated detecting breast cancer recurrence among women treated at Kaiser Permanente Northern California.
Read More